Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

Preclinical Toxicity Study of Clinical Grade Alloge-neic Human Bone Marrow-Derived Clonal Mesenchymal Stromal Cells

بیست و یکمین کنگره پزشکی تولید مثل و شانزدهمین کنگره زیست شناسی و فناوری سلول های بنیادی
Year: 1399
COI: RROYAN21_052
Language: EnglishView: 70
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

Authors

B Tayebi - Department of Applied Cell Sciences, Faculty of Basic Sciences and Advanced Medical Technologies, Royan Institute, ACECR, Tehran, Iran. Advanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stem Cell Biology and
M Babaahmadi - Department of Applied Cell Sciences, Faculty of Basic Sciences and Advanced Medical Technologies, Royan Institute, ACECR, Tehran, Iran. Advanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stem Cell Biology and
M Pakzad - Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
M Hajinasrollah - Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
A Kamali - AO, Research Institute Davos, Davos, Switzerland
SN Hassani - Advanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for S

Abstract:

Objective: Mesenchymal stromal cells (MSCs) have opened a new window for the treatment of inflammatory and non-inflam-matory diseases. Nonetheless, its clinical applications require rigorous control and monitoring procedures to ensure compli-ance with all Good Manufacturing Practices (GMP) principles. For bench-to-bedside development of these newly-emerging therapeutic products, they should pass different stages from in vitro characterization to pre-clinical studies, in addition to clinical trial phases to ensure product safety and efficacy. In this regard, a robust pre-clinical study is critical to ensure product safety. The aim of this study was to determine the toxicity ef-fects of local and systemic injection of human bone marrow-derived clonal mesenchymal stromal cells (hBM-cMSCs) in acute and sub-chronic periods.Materials and Methods: In the present study, hBM-cMSCs were characterized by defined criteria of ISCT for MSCs. The safety and toxicity of hBM-cMSCs population, produced in GMP compatible conditions, were assessed in both sexes of Sprague Dawley (SD) rats through systemic interavenous route and local injection in intervertebral disc (IVD). Changes in body weight, food and water consumption which are important variables in product toxicity tests were assessed. After passing the expected time periods (۱۴ days for the acute period and ۹۰ days for the subchronic period) and sacrificing the rats, labora-tory tests and histopathology of target tissues were performed on designated specimens. Also tumorigenicity was checked in nude mice.Results: Single injection of hBM-cMSCs through intravenous or IVD route during the ۱۴ and ۹۰-days period did not cause significant changes in clinical symptoms and laboratory data of all animals. Ex vivo-expanded and cryopreserved hBMCMSCs did not induce tumor formation in nude mice.Conclusion: The results suggest that local and systemic ad-ministration of allogeneic or xenogeneic hBM-cMSCs in both sexes of SD rats does not impose tumorigenicity and/ or toxicity in acute and subchronic periods.

Keywords:

Toxicity , Bone Marrow Clonal Mesenchymal Stro-mal Cells , Good Manufacturing Practices , Tumorigenicity

Paper COI Code

This Paper COI Code is RROYAN21_052. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/1421333/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Tayebi, B and Babaahmadi, M and Pakzad, M and Hajinasrollah, M and Kamali, A and Hassani, SN,1399,Preclinical Toxicity Study of Clinical Grade Alloge-neic Human Bone Marrow-Derived Clonal Mesenchymal Stromal Cells,21st congress on reproductive biomedicine and 16th congress on stem cell biology & technology ,Tehran,https://civilica.com/doc/1421333

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Scientometrics

The specifications of the publisher center of this Paper are as follows:
Type of center: پژوهشگاه دولتی
Paper count: 6,851
In the scientometrics section of CIVILICA, you can see the scientific ranking of the Iranian academic and research centers based on the statistics of indexed articles.

New Papers

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support